Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 12, 2016. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.1550 per share.
- Transaction Volume: Ranged from 14 to 16 shares per executive.
- Transaction Date: September 9, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with market rules.
Investor Verification Points
- Verify the total number of shares acquired by each named executive (Sir Andrew Witty, Mr. R G Connor, Mr. S Dingemans, Mr. N Hirons, Mr. S A Hussain, Mr. D S Redfern, Ms. C Thomas, Mr. P C Thomson, Dr. P J T Vallance, Ms. E Walmsley, and Mrs. V A Whyte).
- Confirm the transaction price of £16.1550 aligns with the market price on September 9, 2016.
- Note that these acquisitions were made under the ShareReward Plan, consisting of partnership shares and matching shares.